While progress has been made with the approval of sotorasib for treating cancers harboring the KRAS G12C mutation, other KRAS variants still lack targeted therapies.10–17 In this context, targeting KRAS DNA secondary structures, such as G-quadruplexes (G4s), offers an effective approach to cancer therapy compared to conventional strategies that focus on inhibiting the KRAS protein. This evidence concerns the gene KRAS and cancer.